EMBARC
Brief description of study
The dual primary objectives of the study are: 1) to estimate the safety of percutaneous cryoablation with neo-adjuvant trans-arterial embolization of the tumor in patients with T1b renal cell carcinoma, and 2) to estimate the feasibility of patient enrollment in such a trial. The dual primary endpoints are safety, as defined by major adverse events within 90 days of the procedures according to established criteria, and feasibility, defined as being able to enroll 25 patients over two years. Secondary endpoints will include: primary technical success of the percutaneous cryoablation, secondary technical success of the percutaneous cryoablation, technical success of the trans-arterial embolization, percent change to glomerular filtration rate, objective response measured by mRECIST criteria, local recurrence, time-to-progression, cancer-specific survival, and overall survival.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
